fluorescent intensity (MFI) of intracellular κ -B kinase β (IKK β), as a downstream activation product of the NF κ B pathway. MACE events were recorded at follow-up.

Results We recruited 96 patients (average age 61.5 years $\pm$ 13.3; 64.6% male). Patients were followed-up for a median of 187 days (112–222 days). MACE events occurred in 14 patients (14.6%). Using logistic regression analysis, increased total monocyte count ($p<0.032$), Mon2 counts ($p<0.047$) and Mon3 IKK β ($p<0.013$) were significantly predictive of MACE at follow-up (Abstract 125 table 1). Mon2 counts were an independent predictor of MACE after adjusting for age and sex.

Abstract 125 Table 1 Monocyte subpopulations and IKK β predict MACE

	Monocytes	OR (95% CIs)	p Value
Phenotypic characterisation and enumeration	Total Mon	1.002 (1 to 1.004)	0.032
	Mon1	1.001 (0.998 to 1.003)	0.111
	Mon2	1.008 (1.003 to 1.013)	0.047
	Mon3	1.01 (0.999 to 1.022)	0.388
Functional assessment	IKK β Mon1	0.982 (0.944 to 1.022)	0.388
	IKK β Mon2	0.983 (0.948 to 1.019)	0.373
	IKK β Mon3	1.038 (0.993 to 1.086)	0.013

Conclusion Increased total monocyte and Mon2 counts in the first 24 h post infarction is predictive of MACE in STEMI patients. Mon3, despite an assumed role in reparation and fibroblast deposition, are also predictive of MACE. Monocytes remained functionally active throughout the acute and healing phases, and thus may have prognostic implications.

126 DYNAMICS OF THE THREE HUMAN MONOCYTE SUBSETS OVER 30 DAYS IN ST-ELEVATION MYOCARDIAL INFARCTION

doi:10.1136/heartjnl-2012-301877b.126

L D Tapp,* B J Wrigley, B Pamukcu, E Shantsila, G Y H Lip. *City Hospital, Birmingham, UK*

Introduction Monocytes are intimately involved in the pathophysiology of myocardial infarction (MI), with different subsets thought to have distinct roles in cardiac repair. We have described that human monocytes can be divided phenotypically into 3 subsets by their surface expression of CD14, CD16 and CCR2: CD14+CD16–CCR2+ (Mon1, “classical” monocytes), CD14+CD16+CCR2+ (Mon2) and CD14lowCD16+CCR2– (Mon3). Having observed a threefold increase in Mon2 at admission with STEMI, we aimed to establish the dynamics in total monocyte count, subset count and relative proportions of the subsets in the 30 days following ST elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PPCI).

Methods Monocyte subsets were measured by flow cytometry in 50 patients (57.5 $\pm$ 11.7 years, 86% male) with STEMI at 4 time points: within 24 h after PPCI, day 3, day 7 and day 30 after MI onset. All patients underwent PPCI. Exclusion criteria comprised factors known to affect monocyte count.

Results The peak number of total monocytes, Mon1 and Mon2 occurred on day 1, with comparable values on day 3. The total monocyte count and Mon1 reduced significantly by day 30, to levels seen in stable coronary artery disease. Mon2 count reduced significantly earlier, by day 7. No changes were seen in Mon3 count. Mon2 predominates over Mon3 on day 1, with the reverse pattern seen at day 30, where the Mon2 proportion had reduced significantly and the Mon3 proportion had increased significantly.

Conclusions We observed prominent differences in the dynamics of monocyte subsets, particularly the minor subsets (Mon2 and Mon3) which have been suggested to play distinct roles in myocardial reparative processes. The dramatic increase in number of Mon2 after STEMI followed by significant reduction by day suggests a specific role in the acute phase of MI. These novel findings may contribute to further understanding the pathophysiology of the recovery processes following acute MI.

Abstract 126 Table 1

	Day 1	Day 3	Day 7	Day 30	ANOVA p value
Total monocytes (per μ l)	994 $\pm$ 66.2	967 $\pm$ 71.0	861 $\pm$ 70.3	670 $\pm$ 32.4* $\dagger$	<0.0001
Monocyte subsets					
Mon1	810 $\pm$ 57.7	785 $\pm$ 58.5	712 $\pm$ 62.9	557 $\pm$ 31.3* $\dagger$	<0.0001
Mon2	108 $\pm$ 16.0	105 $\pm$ 15.9	73.6 $\pm$ 13.1 $\dagger$	45.3 $\pm$ 5.61* $\dagger$	<0.0001
Mon3	72.2 $\pm$ 7.07	77.1 $\pm$ 10.1	75.1 $\pm$ 5.71	67.3 $\pm$ 4.31	0.55
Relative proportions					
Mon1 %	81.4 $\pm$ 1.61	81.3 $\pm$ 1.60	82.1 $\pm$ 1.55	82.4 $\pm$ 1.33	0.81
Mon2 %	10.9 $\pm$ 1.36	10.5 $\pm$ 1.24	8.58 $\pm$ 1.37	7.36 $\pm$ 1.05* $\dagger$	0.002
Mon3 %	7.61 $\pm$ 0.82	8.23 $\pm$ 0.81	9.37 $\pm$ 0.68	10.3 $\pm$ 0.64* $\dagger$	0.001

* $p<0.05$ vs day 1.

$\dagger p<0.05$ vs day 3.

127 DEMONSTRATION OF INTRACORONARY MICROPARTICLE EXPRESSION AND THEIR ASSOCIATION WITH ACTIVATED PLATELET MONOCYTE AGGREGATE IN HUMAN ST ELEVATION MYOCARDIAL INFARCTION

doi:10.1136/heartjnl-2012-301877b.127

¹C A Mavroudis,* ²D Eleftheriou, ¹B Majumder, ¹R Sapsford, ¹J North, ¹M Lowdell, ²P Brogan, ¹R D Rakhit. ¹Royal Free Hospital, London, UK; ²Institute of Child Health, London, UK

Background Platelets play a central role in the pathophysiology of acute coronary syndrome (ACS). During ACS activated platelets express p-selectin which binds to the p-selectin glycoprotein ligand on the monocyte, forming platelet monocyte aggregates (PMA). PMA expression is a sensitive marker of platelet activation. A microparticle (MP) is a submicron membrane vesicle derived from virtually any cell during various biological processes (cell activation, differentiation or apoptosis). Recent experimental and clinical data point towards a causal effect of MP and mainly platelet derived MP [PMP] in the pathogenesis and disease progression of atherosclerosis and coronary artery disease.

Aim To investigate the relationship between levels of intracoronary MP and PMA in ST elevation ACS.

Methods Patients with ST elevation ACS who underwent primary percutaneous coronary angioplasty were recruited. Blood samples for PMA, MP levels and soluble marker of platelet activation (p-selectin) were collected from the infarct related coronary artery. PMA and MP levels were estimated using fluorescent monoclonal antibodies and flow cytometry. CD61+CD14+CD62P+ events are PMA expressing p-Selectin [activated PMA] and CD61+CD14+CD142+ events are PMA expressing tissue factor [TF+ PMA]. Total MPs were identified as AnV+ MP and PMP as AnV+CD42+/or AnV+CD42+CD62+ MP. Endothelial derived MPs (EMP) were identified as AnV+CD105+CD42– events and/or AnV+CD62E+CD42– events. ELISA was used for p-selectin measurement.

Results The mean total AnV+ MP was 3 661 000/ml of plasma. PMP was statistically higher than EMP $p=0.01$ (mean PMP (SD) 879 986/ml (1 166 000), mean EMP (SD) 89 099/ml (38 867). There was a strongly positive correlation between total Ann V+ MP with

intracoronary p-Selectin and activated PMA [$r^2=0.5$; $p=0.03$, $r^2=0.9$; $p=0.0008$ respectively]. PMP correlated positively with intracoronary p-selectin and activated PMA [$r^2=0.7$; $p=0.01$ and $r^2=0.6$; $p=0.02$ respectively] but they also correlated with TF+ PMA [$r^2=0.7$; $p=0.01$]. CD62P+ PMP was strongly positively related with intracoronary p-Selectin [$r^2=0.9$; $p=0.0001$]. CD105+ EMP also correlated positively with intracoronary p-selectin, activated PMA and TF+ PMA [$r^2=0.7$; $p=0.007$, $r^2=0.6$; $p=0.01$ and $r^2=0.5$; $p=0.04$ for intracoronary p-selectin, activated PMA and TF+ PMA respectively]. CD 62E+ EMP positively correlated with intracoronary p-selectin, activated PMA and TF+ PMA [$r^2=0.6$; $p=0.02$, $r^2=0.6$; $p=0.01$ and $r^2=0.5$; $p=0.03$ respectively].

Conclusions Markers of platelet activation at the site of the culprit lesion during ST elevation ACS correlated strongly not only with total MPs and PMPs but also with endothelial derived MPs. The interaction between activated platelets and monocytes with endothelial cells and the subsequent formation of PMP and EMP during ACS highlights the importance of the downstream effect of activated platelets, monocytes and endothelial cells via MP formation and their contribution in the pathophysiology of ACS.

128 IMPLICATIONS OF LOWERING THE THRESHOLD OF CARDIAC TROPONIN IN THE DIAGNOSIS OF MYOCARDIAL INFARCTION

doi:10.1136/heartjnl-2012-301877b.128

¹K K Lee,* ¹N L Mills, ²D A McAllister, ¹A M D Churchhouse, ³M MacLeod, ⁴M Stoddart, ⁴S Walker, ¹M A Denvir, ¹K A A Fox, ¹D E Newby. ¹Centre for Cardiovascular Science, Edinburgh University, Edinburgh, UK; ²Public Health Sciences, Edinburgh University, Edinburgh, UK; ³Edinburgh Heart Centre, Royal Infirmary of Edinburgh, Edinburgh, UK; ⁴Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK

Introduction The Universal Definition recommends the 99 percentile of cardiac troponin as the diagnostic threshold for myocardial infarction (MI) in patients with suspected acute coronary syndrome if the assay achieves a coefficient of variation (CV) <10%. However, due to imprecision in contemporary assays and concern of over diagnosing myocardial infarction, diagnostic thresholds are currently set at higher concentrations where the assay can achieve CV ≤10%. The aim of this study was to assess the relationship between plasma troponin I concentrations, assay precision and clinical outcomes in patients with suspected acute coronary syndrome.

Methods Using a contemporary sensitive troponin I assay, consecutive patients admitted with suspected acute coronary syndrome (n=2092) were stratified according to the 99th percentile (0.012 ng/ml; CV 20.8%) and current diagnostic threshold (0.05 ng/ml; CV 7.2%) into three groups: <0.012 ng/ml, 0.012–0.049 ng/ml and ≥0.05 ng/ml. Event-free survival (recurrent myocardial infarction or death) at 1 year was compared between patients grouped by troponin I concentration.

Results Plasma troponin concentrations were <0.012 ng/ml in 988 patients (47%), 0.012–0.049 ng/ml in 352 patients (17%) and ≥0.05 ng/ml in 752 patients (36%). At 1 year, patients with troponin concentrations 0.012–0.049 ng/ml were more likely to be dead or readmitted with recurrent myocardial infarction compared to those with troponin concentrations <0.012 ng/ml (13% vs 3%; OR 4.8, 95% CI 3.0 to 7.7; $p<0.001$). Compared to troponin ≥0.050 ng/ml, patients with troponin 0.012–0.049 ng/ml had a higher risk profile but were less likely to be diagnosed with, or investigated and treated for, acute coronary syndrome.

Conclusions Lowering the diagnostic threshold to the 99th percentile and accepting greater assay imprecision would identify those at high-risk of recurrent MI and death, but increase the diagnosis of MI

by 46%. It remains to be established whether reclassifying and treating these patients as MI would improve outcome.

Abstract 128 Figure 1

Abstract 128 Figure 2

129 THE PROGNOSTIC VALUE OF A 7-WEEK HIGH SENSITIVITY TROPONIN T LEVEL AFTER AN ACUTE CORONARY SYNDROME

doi:10.1136/heartjnl-2012-301877b.129

D S Ang,* M P Kao, C C Lang, E Dow, A D Struthers. University of Dundee, Dundee, UK

Background High sensitivity Troponin T (HS-TnT) is a well established diagnostic and prognostic tool in acute coronary syndrome (ACS). However, its role in the convalescence phase after an ACS is unknown. Our first aim was to assess the prognostic utility of a single HS-TnT level at 7-week post ACS. Second, we evaluated whether any serial changes in HS-TnT between the index admission and 7 weeks post ACS had any link with prognosis. Third, we assessed whether the prognostic utility of HS-TnT is independent of various echocardiographic abnormalities.

Methods We measured HS-TnT levels in 326 consecutive patients at 7 weeks after an ACS event. The composite end point of death from any cause or acute myocardial infarction (AMI) was evaluated over a median duration of 30 months.